PTGXProtagonist Therapeutics, Inc.Running, no new patients
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Polycythemia Vera
1Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.3
2 insiders sold shares within a month
Since May 12, 2026 · was worth 10, fading over time
Worry score1
Score over time
- Stage
- Phase 3
- Patients
- 46 (final count)
- Started
- Jan 22, 2024
- Main results expected
- Apr 1, 2026
- Fully finished
- Apr 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Hematocrit
Measured over: 0-2 years
Phlebotomies
Measured over: 0-2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.3, since 2026-05-12, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06033586 · record last updated 2025-08-06 · checked 2026-11-09 15:47 UTC